The State of AI in Drug Discovery

- Friends! This biopsy has a ticker symbol. The GEN summit on November 4 treats AI drug discovery like a critical relay window. Leaders from Eli Lilly, Xaira, and Edison Scientific are mapping how foundation models shift R&D timelines. It’s not magic; it’s infrastructure. We’re seeing the first AI-guided molecules enter clinics, proving that generative design plus experimental feedback equals real patient translation. I treated cats. Same thing, only more honest—biology is just complex code waiting for a clean hash manifest. No panic here, just a diagnostic dance toward faster cures. The inflection point is now.